Jason Robert Stubbs MD
Associate Professor, Internal Medicine, University Kansas School of Medicine
Join to View Full Profile
3901 Rainbow Blvd# MS3002Kansas City, KS 66160
Phone+1 913-588-6074
Fax+1 913-588-3867
Dr. Stubbs is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of Kansas School of MedicineFellowship, Nephrology, 2005 - 2007
- University of Kansas School of MedicineResidency, Internal Medicine, 2002 - 2005
- University of Kansas School of MedicineClass of 2002
Certifications & Licensure
- MO State Medical License 2021 - 2026
- KS State Medical License 2005 - 2025
- American Board of Internal Medicine Nephrology
Awards, Honors, & Recognition
- Patient-Centered Specialty Practice Recognition Program National Committee for Quality Assurance, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Role of Extrarenal 1-Alpha-Hydroxylase in Patients With End Stage Renal Disease Start of enrollment: 2008 May 01
- Impact of Vitamin D Therapies on Chronic Kidney Disease Start of enrollment: 2010 Oct 01
- Differential Effects of Ergocalciferol and Cholecalciferol Therapies in Chronic Kidney Disease Start of enrollment: 2011 Oct 01
Publications & Presentations
PubMed
- Osteopontin deletion attenuates cyst growth but exacerbates fibrosis in mice with cystic kidney disease.Kyle P Jansson, Jordan Kuluva, Shiqin Zhang, Taylor Swanson, Yan Zhang
Physiological Reports. 2024-09-01 - 2 citationsCorrection of Vascular Calcification and Hyperphosphatemia in CKD Rats Treated with ASARM Peptide.Peter S Rowe, Ellen M McCarthy, Alan L Yu, Jason R Stubbs
Kidney360. 2022-10-27 - 6 citationsCritical Role of Osteopontin in Maintaining Urinary Phosphate Solubility in CKD.Jason R Stubbs, Shiqin Zhang, Kyle P Jansson, Timothy A Fields, Joseph Boulanger
Kidney360. 2022-09-29
Lectures
- Kidney, Bone, and Vasculature: Is the Gut a New Piece of the Puzzle?American Society of Nephrology Kidney Week 2019 - Washington, D.C. - 11/9/2019
Other
- Overview of the causes and treatment of hyperphosphatemiaStubbs JR, Yu AS
http://www.uptodate.com/contents/overview-of-the-causes-and-treatment-of-hyperphosphatemia
UpToDate, Wolters Kluwer Health - 2013-03-04
Press Mentions
- TMAO Implicated as a Cardiovascular Risk Factor in CKDAugust 5th, 2015
Grant Support
- Exploring The Interrelationships Of Mineral Metabolism Pathways In Kidney DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases2010–2011
- Clinical Trial: Extrarenal 1-Alpha-Hydroxylase In End-Stage Renal DiseaseNational Center For Research Resources2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
